Plain-English translation of NCT05062707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how intensive cancer treatment—such as chemotherapy and radiation—may cause young cancer patients to age faster at a cellular level. This study will follow young adults before they start cancer treatment and again one year later, measuring specific markers in the blood that show signs of cellular aging and stress on blood vessels.
Young cancer survivors have an increased risk of heart disease later in life, and scientists believe this may be linked to accelerated aging caused by cancer treatment. This study aims to identify which patients are at highest risk and what happens to their cells and blood vessels during therapy, so doctors can better protect their long-term health.
You likely qualify if…
You likely don't qualify if…
You will have blood tests and possibly other measurements taken before you start your cancer treatment, and then again one year later. The study team will also collect information about your health, lifestyle, and cancer diagnosis to see which factors affect aging markers most. The main commitment is attending two study visits about a year apart while you receive your regular cancer care.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Netherlands
University Medical Center Groningen
Collaborators
UMCG Kanker Researchfonds
Enrollment target
~120 participants
Started
February 2022
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 39 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
J. Nuver, MD, PhD
University Medical Center Groningen
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.